OncoMatch/Clinical Trials/NCT06386146
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Is NCT06386146 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies JAB-30355 for solid tumors.
Treatment: JAB-30355 — This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: TP53 y220c
Have documentation of confirmed TP53 Y220C mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status score of 0 or 1
Prior therapy
Must have received: systemic therapy — for that tumor type and stage
Has been treated with at least one line of systemic therapy for that tumor type and stage
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
LVEF 50% assessed by ECHO or MUGA; QTcF > 470 msec
Adequate hematological, renal and hepatic function and appropriate coagulation condition. LVEF 50% assessed by ECHO or MUGA. QTcF > 470 msec.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Denver, Colorado
- Research site · Lake Mary, Florida
- Research site · St Louis, Missouri
- Research site · Canton, Ohio
- Research site · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06386146 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Does this trial require TP53?
Yes, TP53 y220c is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify